Immuneering Corp
IMRX
Company Profile
Business description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Contact
245 Main Street
Second Floor
CambridgeMA02142
USAT: +1 617 500-8080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,271.60 | 5.50 | -0.06% |
| CAC 40 | 7,919.62 | 14.64 | -0.18% |
| DAX 40 | 24,236.94 | 150.99 | -0.62% |
| Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
| FTSE 100 | 9,452.77 | 9.90 | 0.10% |
| HKSE | 25,714.89 | 273.54 | 1.08% |
| NASDAQ | 22,521.70 | 172.91 | -0.76% |
| Nikkei 225 | 47,261.31 | 413.99 | 0.88% |
| NZX 50 Index | 13,311.70 | 34.71 | 0.26% |
| S&P 500 | 6,644.31 | 10.41 | -0.16% |
| S&P/ASX 200 | 8,964.30 | 4.40 | -0.05% |
| SSE Composite Index | 3,864.93 | 0.30 | -0.01% |